Closeup of a stock market broker working with graphs on digital tablet at office. Rear view of stock agent reading bad report and graph. Back view of multiethnic businessman analyzing fall sales.

Clovis Oncology, Inc. [CLVS] is following upward trend in the market concluded with the last trading session. The shares of the Healthcare sector company has a current value of $5.76 after CLVS shares went up by 0.94% during the last trading session. One of the reasons why Healthcare stocks may go bullish is increased momentum in the press.

Clovis Oncology, Inc. [NASDAQ:CLVS]: Analyst Rating and Earnings

Its stock price has been found in the range of 4.98 to 34.63. This is compared to its latest closing price of $5.71.

Keep looking out for the next-scheduled quarterly financial results that this company is expected to put out, which is slated to occur on Tue 29 Oct (In 46 Days).

(adsbygoogle = window.adsbygoogle || []).push({});

Fundamental Analysis of Clovis Oncology, Inc. [CLVS]

Now let’s turn to look at profitability: with a current Operating Margin for Clovis Oncology, Inc. [CLVS] sitting at -349.95 and its Gross Margin at +76.86.

This company’s Return on Total Capital is -47.86, and its Return on Invested Capital has reached -50.10%. Its Return on Equity is -143.16, and its Return on Assets is -45.99. These metrics suggest that this Clovis Oncology, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Clovis Oncology, Inc. [CLVS] has generated a Total Debt to Total Equity ratio of 393.60. Similarly, its Total Debt to Total Capital is 79.74, while its Total Debt to Total Assets stands at 66.62. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is -25.32, and its Long-Term Debt to Total Capital is 392.90.

What about valuation? This company’s Enterprise Value to EBITDA is -1.05. The Enterprise Value to Sales for this firm is now 2.89, and its Total Debt to Enterprise Value stands at 0.58. Clovis Oncology, Inc. [CLVS] has a Price to Book Ratio of 6.47.

Shifting the focus to workforce efficiency, Clovis Oncology, Inc. [CLVS] earns $203,821 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 8.16 and its Total Asset Turnover is 0.12. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 4.34 and its Current Ratio is 4.55. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Clovis Oncology, Inc. [CLVS] has 54.14M shares outstanding, amounting to a total market cap of $309.14M. Its stock price has been found in the range of 4.98 to 34.63. At its current price, it has moved down by -83.36% from its 52-week high, and it has moved up 15.74% from its 52-week low.

This stock’s Beta value is currently 1.89, which indicates that it is 8.86% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 38.39. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Clovis Oncology, Inc. [CLVS] a Reliable Buy?

Shares of Clovis Oncology, Inc. [CLVS], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.